Observational Study Protocol: LIVER-R

ClinicalTrials.gov ID: NCT06252753

Public ClinicalTrials.gov record NCT06252753. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Observational Multi-Center Study to Evaluate Real-World Treatment Outcomes With or Without Durvalumab-Based Regimens in Hepatobiliary Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multi-country, multi-center, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with or without a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of regimens (durvalumab-based or otherwise) in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, treatment provider characteristics, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, time to treatment discontinuation, recurrence-free survival, and time to treatment recurrence).

Study identification

NCT ID: NCT06252753
Recruitment status: Recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: AstraZeneca; Industry
Enrollment: 4,000 participants

Conditions and interventions

Conditions

Hepatobiliary Cancers

Interventions

Other

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2023
Primary completion: Dec 29, 2030
Completion: Dec 29, 2030
Last update posted: Aug 12, 2026

2023 – 2030

United States locations

U.S. sites: 24
U.S. states: 14
U.S. cities: 24

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35233-1932	Recruiting
Research Site	Mobile	Alabama	36604	Recruiting
Research Site	Phoenix	Arizona	85004	Recruiting
Research Site	Coronado	California	92118	Recruiting
Research Site	Los Angeles	California	90048	Recruiting
Research Site	Walnut Creek	California	94598	Recruiting
Research Site	Clermont	Florida	34711	Recruiting
Research Site	Gainesville	Florida	32610	Recruiting
Research Site	Tampa	Florida	33606	Recruiting
Research Site	Augusta	Georgia	30912	Recruiting
Research Site	Evergreen Park	Illinois	60805	Recruiting
Research Site	Hinsdale	Illinois	60521	Recruiting
Research Site	Baton Rouge	Louisiana	70808	Recruiting
Research Site	Boston	Massachusetts	02215	Recruiting
Research Site	Osage Beach	Missouri	65065	Recruiting
Research Site	White Plains	New York	10601	Recruiting
Research Site	Canton	Ohio	44718	Recruiting
Research Site	Bethlehem	Pennsylvania	18015	Recruiting
Research Site	Lancaster	Pennsylvania	17604	Recruiting
Research Site	Philadelphia	Pennsylvania	19141	Recruiting
Research Site	Pittsburgh	Pennsylvania	15212	Recruiting
Research Site	Dallas	Texas	75390-8567	Recruiting
Research Site	Temple	Texas	76508	Recruiting
Research Site	Spokane	Washington	99204	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 135 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06252753, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 12, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06252753 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →